J P Dutcher

Summary

Publications

  1. ncbi request reprint High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma
    Janice Dutcher
    New York Medical College, Bronx, USA
    Oncology (Williston Park) 16:3. 2002
  2. ncbi request reprint Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines
    J Dutcher
    Our Lady of Mercy New York Medical College, Bronx 10466, USA
    Med Oncol 18:209-19. 2001
  3. ncbi request reprint The role of Epstein-Barr virus and elevated levels of tumor necrosis factor in determining prognosis in Asian peripheral T-cell lymphomas
    Janice P Dutcher
    Department of Medicine, New York Medical College, Our Lady of Mercy Cancer Center, 600 East 233rd Street, Bronx, NY10466, USA
    Leuk Res 27:467-9. 2003
  4. doi request reprint Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies
    Janice P Dutcher
    Montefiore Medical Center North Division New York Medical College, 600 East 233rd Street, Bronx, NY, 10466, USA
    Med Oncol 26:202-9. 2009
  5. ncbi request reprint Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890)
    Janice P Dutcher
    Our Lady of Mercy Cancer Center, NY Med College Bronx, New York 10466, USA
    Med Oncol 20:271-81. 2003
  6. ncbi request reprint Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993)
    Janice P Dutcher
    Albert Einstein College NY, Bronx, NY, USA
    Leuk Lymphoma 46:377-85. 2005
  7. ncbi request reprint Mammalian target of rapamycin (mTOR) Inhibitors
    Janice P Dutcher
    Our Lady of Mercy Cancer Center, New York Medical College, 600 East 233rd Street, Bronx, NY 10466, USA
    Curr Oncol Rep 6:111-5. 2004
  8. ncbi request reprint Mammalian target of rapamycin inhibition
    Janice P Dutcher
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, Bronx, New York 10466, USA
    Clin Cancer Res 10:6382S-7S. 2004
  9. doi request reprint Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy
    Janice P Dutcher
    Oncology, New York Medical College, Montefiore, North Division, 600 East 233rd Street, Bronx, NY 10466, USA
    Med Oncol 28:1530-3. 2011
  10. ncbi request reprint Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study
    Janice P Dutcher
    Our Lady of Mercy Cancer Center New York Medical College, Bronx, New York 10466, USA
    Cancer 104:2392-9. 2005

Detail Information

Publications57

  1. ncbi request reprint High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma
    Janice Dutcher
    New York Medical College, Bronx, USA
    Oncology (Williston Park) 16:3. 2002
  2. ncbi request reprint Kidney cancer: the Cytokine Working Group experience (1986-2001): part II. Management of IL-2 toxicity and studies with other cytokines
    J Dutcher
    Our Lady of Mercy New York Medical College, Bronx 10466, USA
    Med Oncol 18:209-19. 2001
    ..Currently, the CWG is conducting studies with new approaches to IL-2 therapy, as well as planning trials with new agents for treatment of renal cell cancer. This review describes these efforts conducted over the past 15 yr...
  3. ncbi request reprint The role of Epstein-Barr virus and elevated levels of tumor necrosis factor in determining prognosis in Asian peripheral T-cell lymphomas
    Janice P Dutcher
    Department of Medicine, New York Medical College, Our Lady of Mercy Cancer Center, 600 East 233rd Street, Bronx, NY10466, USA
    Leuk Res 27:467-9. 2003
    ..The current study reports correlations of EBV + T-cell lymphoma with higher levels of TNF, and suggests some prognostic correlations...
  4. doi request reprint Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies
    Janice P Dutcher
    Montefiore Medical Center North Division New York Medical College, 600 East 233rd Street, Bronx, NY, 10466, USA
    Med Oncol 26:202-9. 2009
    ..Conclusion Temsirolimus appears to be efficacious in patients with clear cell and non-clear cell histologies and can, therefore, be used for the treatment of all types of RCC...
  5. ncbi request reprint Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890)
    Janice P Dutcher
    Our Lady of Mercy Cancer Center, NY Med College Bronx, New York 10466, USA
    Med Oncol 20:271-81. 2003
    ....
  6. ncbi request reprint Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993)
    Janice P Dutcher
    Albert Einstein College NY, Bronx, NY, USA
    Leuk Lymphoma 46:377-85. 2005
    ..Combination therapy with other differentiating agents may be useful in this disease...
  7. ncbi request reprint Mammalian target of rapamycin (mTOR) Inhibitors
    Janice P Dutcher
    Our Lady of Mercy Cancer Center, New York Medical College, 600 East 233rd Street, Bronx, NY 10466, USA
    Curr Oncol Rep 6:111-5. 2004
    ..Ongoing clinical trials are evaluating renal cell cancer and other malignancies using therapy with mTOR inhibitors. These agents are more likely to induce growth inhibition rather than tumor regression...
  8. ncbi request reprint Mammalian target of rapamycin inhibition
    Janice P Dutcher
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, Bronx, New York 10466, USA
    Clin Cancer Res 10:6382S-7S. 2004
    ..Additional clinical trials that use agents that inhibit mTOR are ongoing...
  9. doi request reprint Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy
    Janice P Dutcher
    Oncology, New York Medical College, Montefiore, North Division, 600 East 233rd Street, Bronx, NY 10466, USA
    Med Oncol 28:1530-3. 2011
    ..In summary, this regimen is associated with a high response rate, overall improvement in progression free survival and occasional meaningful long-term survival in a disease expected to be fatal within one year...
  10. ncbi request reprint Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy: E4896, an Eastern Cooperative Oncology Group Study
    Janice P Dutcher
    Our Lady of Mercy Cancer Center New York Medical College, Bronx, New York 10466, USA
    Cancer 104:2392-9. 2005
    ..The current study evaluated the response rate and 6-month time to disease progression of the antiangiogenesis agent carboxyamidotriazole (CAI) in patients with metastatic renal cell carcinoma (RCC)...
  11. doi request reprint A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia
    Janice P Dutcher
    New York Medical College, 600 East 233rd Street, Bronx, NY 10466, USA
    Med Oncol 27:728-35. 2010
    ..Carboplatin plus mitoxantrone are highly active in CMLBC, with marrow aplasia as the dose-limiting toxicity, and these agents deserve further study in CMLBC, perhaps in combination with tyrosine kinase inhibitors...
  12. doi request reprint Experience with sorafenib and the elderly patient
    Janice P Dutcher
    Department of Oncology, Montefiore Medical Center North Division New York Medical College, 600 East 233rd Street, Bronx, NY 10466, USA
    Med Oncol 27:1359-70. 2010
    ..The goal of these recommendations is to maximize the clinical benefit of sorafenib in the elderly patient population through appropriate use...
  13. ncbi request reprint Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma
    Janice Dutcher
    New York Medical College, Bronx, USA
    Oncology (Williston Park) 16:4-10. 2002
    ..The most promising regimens have included various IL-2-based biochemotherapy regimens in other patients. Randomized studies confirming the superiority of these regimens over high-dose IL-2 therapy are needed...
  14. ncbi request reprint Immunotherapy: are we making a difference?
    J P Dutcher
    New York Medical College and Our Lady of Mercy Cancer Centre, Bronx 10466, USA
    Curr Opin Urol 10:435-9. 2000
    ..Anti-proliferative effects of immunotherapy produce prolongation of stable disease, and new agents are being developed to enhance this approach...
  15. ncbi request reprint Angiogenesis and melanoma
    J P Dutcher
    New York Medical College, Our Lady of Mercy Cancer Center, 600 East 233rd Street, Bronx, NY 10466, USA
    Curr Oncol Rep 3:353-8. 2001
    ..Interruption of the tumor-sustaining process of angiogenesis has become a major focus of anticancer drug development. Promising agents are in both preclinical and clinical development. Several may prove to be clinically important...
  16. ncbi request reprint Clinical impact of multidrug resistance in acute leukemia
    Janice P Dutcher
    Department of Medicine, Our Lady of Mercy Cancer Center, New York Medical College, 600 East 233rd Street, Bronx, NY 10466, USA
    Leuk Res 26:323-5. 2002
  17. ncbi request reprint Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma
    J A Sparano
    Department of Oncology, Albert Einstein Cancer Center, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA
    J Clin Oncol 14:3026-35. 1996
    ....
  18. ncbi request reprint Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282
    Y Novik
    Cancer Center, Our Lady of Mercy Hospital, New York Medical College, Bronx, New York 10466, USA
    Med Oncol 16:261-6. 1999
    ..There were four treatment-related deaths and four life-threatening toxicities. Because of low response rates and relatively high toxicities the studied compounds were not deemed worth further investigation for advanced gastric cancer...
  19. ncbi request reprint Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide
    D Unnikrishnan
    Our Lady of Mercy Cancer Center and Division of Cardiology, Our Lady of Mercy Medical Center, Bronx, NY 10466, USA
    Blood 97:1514-6. 2001
    ..Early recognition of the arrhythmia or correction of contributory factors is important because arsenic induced ventricular arrhythmias are known to be resistant to most chemical methods and electrical cardioversion...
  20. pmc Biologic response modifiers in gynecologic malignancies
    J P Dutcher
    Department of Oncology, Montefiore Medical Center, Bronx, NY 10467
    Yale J Biol Med 61:367-78. 1988
    ..Both of these hypothesis have pre-clinical data to support them. This paper presents the pre-clinical and clinical work currently available for consideration of future use...
  21. ncbi request reprint A phase 2 study of moderate dose interleukin-2 and granulocyte-macrophage colony-stimulating factor in patients with metastatic or unresectable renal cell carcinoma
    Lydia Koulova
    Comprehensive Cancer Center at Our Lady of Mercy Medical Center, Bronx, New York 10466, USA
    J Immunother 28:576-81. 2005
    ....
  22. ncbi request reprint Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma
    Constantin A Dasanu
    New York Medical College, Comprehensive Cancer Center, Our Lady of Mercy Medical Center, 600 East 233rd Street, Bronx, NY 10466, USA
    South Med J 100:328-30. 2007
    ..A thorough clinicolaboratory investigation did not reveal any evidence of jaundice, B12 deficiency, anemia, carotenemia, hypothyroidism, or any other disorder of endocrine or metabolic etiology...
  23. ncbi request reprint Characterization of bone metastases in patients with renal cell cancer
    G U Adiga
    Comprehensive Cancer Center and Department of Medicine, Our Lady of Mercy Medical Center, New York Medical College, Bronx, New York, USA
    BJU Int 93:1237-40. 2004
    ..Bone lesions contribute to significant morbidity and mortality, and although present in up to half of patients with RCC, their behaviour and response to therapy have not been well characterized...
  24. ncbi request reprint Metastatic melanoma: is biochemotherapy the future?
    Doru T Alexandrescu
    New York Medical College, Our Lady of Mercy Medical Center, Comprehensive Cancer Center, Bronx, NY 10466, USA
    Med Oncol 22:101-11. 2005
    ....
  25. ncbi request reprint Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome associated with high-dose interleukin-2 for the treatment of metastatic melanoma
    Doru T Alexandrescu
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx, New York 10466, USA
    J Immunother 28:144-7. 2005
    ..coli O157, after IL-2 or IL-2-containing biochemotherapy, as well as in TTP caused by interferon-alpha. This cytokine profile could reflect a common cause, or just the presence of similar pathways involved...
  26. doi request reprint Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study
    Michael B Atkins
    Division of Hematology Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Cancer 113:2139-45. 2008
    ..The authors tested the efficacy of a regimen including TMZ, thalidomide, and whole brain radiation therapy (WBRT) in patients with brain (CNS) metastases from melanoma...
  27. ncbi request reprint The role of carbonic anhydrase IX overexpression in kidney cancer
    Thambi Dorai
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx, NY 10466 2697, USA
    Eur J Cancer 41:2935-47. 2005
    ..Finally, our studies emphasize the need for a more refined strategy using signal transduction therapeutics to inhibit the cell surface carbonic anhydrases for the management of this malignancy...
  28. ncbi request reprint Role of carbonic anhydrases in the progression of renal cell carcinoma subtypes: proposal of a unified hypothesis
    Thambi Dorai
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx, New York 10466, USA
    Cancer Invest 24:754-79. 2006
    ....
  29. ncbi request reprint Oblimersen and alpha-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium
    Kim Margolin
    Division of Medical Oncology, City of Hope National Medical Center, 1500 East Duarte Road, Duarte, CA 91010 3000, USA
    J Cancer Res Clin Oncol 133:705-11. 2007
    ..Trial endpoints were antitumor efficacy and toxicity, pharmacokinetics, and evidence of apoptosis in peripheral blood mononuclear cells...
  30. ncbi request reprint Phase I trial of BAY 50-4798, an interleukin-2-specific agonist in advanced melanoma and renal cancer
    Kim Margolin
    City of Hope National Medical Center, Duarte, California 91010 3000, USA
    Clin Cancer Res 13:3312-9. 2007
    ..This phase I study was designed to determine the maximum tolerated dose (MTD) and safety of BAY 50-4798, screen for tumor response, and assess pharmacokinetics...
  31. ncbi request reprint Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma
    Robert J Motzer
    Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    J Clin Oncol 25:3958-64. 2007
    ..A recommended dose and safety profile for the combination of temsirolimus and interferon alfa (IFN) were determined in patients with advanced RCC...
  32. ncbi request reprint Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Chicago, Maywood, IL 60153, USA
    J Immunother 30:839-46. 2007
    ..Despite clinical efficacy, the study was closed prematurely owing to excess toxicity. Although all serious adverse events resolved, this degree of toxicity is unacceptable for an outpatient treatment regimen...
  33. ncbi request reprint Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma
    David F McDermott
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, E KS 153, Boston, MA 02215, USA
    J Clin Oncol 23:133-41. 2005
    ..The Cytokine Working Group conducted a randomized phase III trial to determine the value of outpatient interleukin-2 (IL-2) and interferon alfa-2b (IFN) relative to high-dose (HD) IL-2 in patients with metastatic renal cell carcinoma...
  34. ncbi request reprint Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases
    Lydia Koulova
    Comprehensive Cancer Center at Our Lady of Mercy Medical Center, New York Medical College, Bronx, New York 10466, USA
    Am J Hematol 78:49-54. 2005
    ..We conclude that rituximab is a useful immunomodulating adjunct in the treatment of refractory ITP and TTP...
  35. ncbi request reprint A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893)
    Roland T Skeel
    Medical College of Ohio, Toledo, Ohio, USA
    Cancer Invest 21:41-6. 2003
    ....
  36. ncbi request reprint Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial
    Joseph I Clark
    Cardinal Bernardin Cancer Center, Loyola University Medical Center, 2160 South First Avenue, Maywood, IL 60153, USA
    J Clin Oncol 21:3133-40. 2003
    ..This prospective, randomized, controlled phase III trial assessed high-dose bolus interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell carcinoma (RCC)...
  37. ncbi request reprint Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group
    Arthur I Radin
    Department of Internal Medicine, Division of Hematology Oncology, Cornell University Medical School, New York, New York, USA
    Cancer 98:100-9. 2003
    ....
  38. ncbi request reprint Interleukin-2 based therapy for kidney cancer
    Janice P Dutcher
    Our Lady of Mercy Cancer Center, New York Medical College, USA
    Cancer Treat Res 116:155-72. 2003
    ..Current recommendations are to use the simplest and most feasible in a given institution. Certainly high dose IL-2 remains the standard regimen to which all others are measured...
  39. ncbi request reprint Phase II study of interferon gamma in malignant carcinoid tumors (E9292): a trial of the Eastern Cooperative Oncology Group
    Keith Stuart
    Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Invest New Drugs 22:75-81. 2004
    ..To determine the safety and efficacy of treatment with gamma interferon (IFNgamma) in patients with metastatic carcinoid tumor...
  40. ncbi request reprint Probable veno-occlusive disease after treatment with gemtuzumab ozogamicin in a patient with acute myeloid leukemia and a history of liver transplantation for familial hemochromatosis
    Kevin P O'Boyle
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx, NY 10466, USA
    Med Oncol 20:379-84. 2003
    ..He did not have a history of hematopoietic stem cell transplantation, which is usually the case in AML patients who develop veno-occlusive disease of the liver after treatment with Mylotarg...
  41. ncbi request reprint Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma
    Michael B Atkins
    Department of Medicine, Division of Hematology Oncology, Beth Israel Deaconess Medical Center, E Campus, Kirstein 158, Boston, MA 02215, USA
    J Clin Oncol 22:909-18. 2004
    ..To evaluate the efficacy, safety, and pharmacokinetics of multiple doses of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma (RCC)...
  42. ncbi request reprint Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia
    Merat Karbasian-Esfahani
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx 10466, USA
    Cancer 101:1414-9. 2004
    ..New chemotherapeutic agents and drug combinations were employed in refractory patients to overcome drug resistance...
  43. ncbi request reprint Fatal intra-alveolar hemorrhage after rituximab in a patient with non-Hodgkin lymphoma
    Doru T Alexandrescu
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx, NY 10466, USA
    Leuk Lymphoma 45:2321-5. 2004
    ..A review of the pertinent literature is provided. The possible pathogenetic mechanisms, including the role of cytokines, cytotoxic T-lymphocytes and CD 20 positive T-cells in relation to the administration of rituximab are discussed...
  44. ncbi request reprint Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma
    David M Nanus
    Department of Medicine, Weill Medical College of Cornell University, New York, New York, USA
    Cancer 101:1545-51. 2004
    ..Based on the antitumor activity of doxorubicin and gemcitabine in collecting duct carcinoma of the kidney, the authors used this combination to treat selected patients with sarcomatoid or rapidly progressing RCC...
  45. ncbi request reprint Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody
    Kenneth A Foon
    Abgenix, Inc, Fremont, CA, USA
    Int J Radiat Oncol Biol Phys 58:984-90. 2004
    ..Therapy was generally well tolerated without statistically significant adverse events. Monoclonal antibody blockade of EGFR represents a new and exciting direction in cancer therapy...
  46. ncbi request reprint Renal parenchymal tumors and lymphoma in the same patient: case series and review of the literature
    Anuradha Kunthur
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx, New York 10466, USA
    Am J Hematol 81:271-80. 2006
    ....
  47. ncbi request reprint The prognostic role of detection of circulating melanoma cells in the blood
    Janice P Dutcher
    J Clin Oncol 21:757-9. 2003
  48. ncbi request reprint A review of evidence-based treatment of stage IIB to stage IV melanoma
    Saji Eapen
    Our Lady of Mercy Cancer Center, New York Medical College, Bronx, New York 10466, USA
    Cancer Invest 23:323-37. 2005
  49. ncbi request reprint Blastic phase of chronic myelogenous leukemia
    Evelyn L Morris
    New York Medical College, Bronx, NY 10466, USA
    Clin Adv Hematol Oncol 3:547-52. 2005
    ..We review the molecular biology and evolution of treatment of the blastic phase of CML...
  50. ncbi request reprint Renal medullary carcinoma: the Bronx experience
    A Ari Hakimi
    Department of Urology, Montefiore Medical Center, Bronx, New York 10467, USA
    Urology 70:878-82. 2007
    ..We present our clinical experience with 9 cases of RMC during a 10-year period and briefly review the published data...
  51. ncbi request reprint Innovations and challenges in renal cancer: consensus statement from the first international conference
    Michael B Atkins
    Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA
    Clin Cancer Res 10:6277S-81S. 2004
  52. ncbi request reprint Cardiac monitoring of patients receiving arsenic trioxide therapy
    Dilip Unnikrishnan
    Our Lady of Mercy Cancer Center, 600 East 233rd Street, Bronx, NY, USA
    Br J Haematol 124:610-7. 2004
    ..QTc prolongation, transient arrhythmias and clinically significant arrhythmias were seen with therapeutic doses of ATO...
  53. ncbi request reprint Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group
    Hossein Borghaei
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Immunother 30:455-67. 2007
    ....
  54. ncbi request reprint Effects of desialylation of ovine submaxillary gland mucin (OSM) on humoral and cellular immune responses to Tn and sialylated Tn
    Kevin P O'Boyle
    Our Lady of Mercy Cancer Center, New York Medical College, Bronx, NY 10466, USA
    Cancer Immun 6:5. 2006
    ..It is thought that these large erythematous, nonindurated cellular reactions are antibody-mediated Arthus-like reactions. OSM, and especially dOSM, were also found to inhibit lymphocyte proliferation...
  55. ncbi request reprint Therapeutic potential of curcumin in prostate cancer--V: Interference with the osteomimetic properties of hormone refractory C4-2B prostate cancer cells
    Thambi Dorai
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, Bronx, New York 10466, USA
    Prostate 60:1-17. 2004
    ..This study focuses on the potential of curcumin, a plant based non-toxic tyrosine kinase inhibitor in interfering with the development of bone like properties of C4-2B, a highly metastatic derivative of LNCaP prostate cancer cell line...
  56. ncbi request reprint Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease
    Doru T Alexandrescu
    Comprehensive Cancer Center, Our Lady of Mercy Medical Center, New York Medical College, NY 10446, USA
    Leuk Lymphoma 47:641-56. 2006
    ..Although significant, the toxicities associated with this regimen were manageable...
  57. ncbi request reprint Blastic phase of chronic myelogenous leukemia
    Merat Karbasian Esfahani
    Our Lady of Mercy Comprehensive Cancer Center, 600 East 233rd Street, Bronx, NY 10466, USA
    Curr Treat Options Oncol 7:189-99. 2006
    ..The prognosis of CML in blast crisis remains disappointing, despite great efforts. Currently, the most successful strategy for improving survival in CML is by prolonging the chronic phase and delaying the onset of blast crisis...